Business Context and Reporting Period
This Form 8-K, filed on August 29, 2023, reports on events occurring on August 28, 2023, regarding First Light Acquisition Group, Inc. ("FLAG") and its business combination with Calidi Biotherapeutics, Inc. ("Calidi"). Following a special meeting of stockholders held August 22–28, 2023, FLAG stockholders approved the merger. Upon consummation, FLAG will be renamed Calidi Biotherapeutics, Inc. ("New Calidi").
Key Financial Metrics and Capital Structure
- Trust Account Value: As of August 30, 2023, the estimated per-share redemption price from the Trust Account is approximately $10.49.
- Series B Financing: Calidi previously secured a commitment of $25.0 million for 1,000,000 shares of Series B Convertible Preferred Stock at $25.00 per share.
- Forward Purchase Agreement (FPA): Entered into with Meteora Strategic Capital, LLC and affiliates ("Seller") for an OTC Equity Prepaid Forward Transaction involving up to 340,000 shares of Class A Common Stock.
- Non-Redemption Agreement: Seller agreed to reverse the redemption of 129,524 shares. New Calidi will pay Seller approximately $680,000 in cash for these non-redeemed shares upon closing.
- Additional Seller Investment: Seller committed to invest approximately $1.02 million in Series B Preferred Stock through Calidi Cure LLC.
Material Changes and Stockholder Votes
On August 28, 2023, FLAG stockholders approved eight proposals, including the business combination, the amended certificate of incorporation, governance provisions, equity incentive plans, and the election of a new board of directors. Key vote totals included:
- Business Combination Approval: 7,039,109 votes For; 242,945 votes Against.
- Charter and Governance Proposals: Received between 6,943,786 and 7,039,109 votes For, with "Against" votes ranging from 242,945 to 338,268.
- Board Election: Seven directors were elected, including Allan Camaisa (CEO), with vote counts ranging from 6,970,991 to 7,241,490 For.
Outlook, Risks, and Unusual Items
Forward Purchase Agreement Mechanics: The FPA includes a "Reset Price" initially set at $10.00, which may be reduced if New Calidi issues stock at a lower price. The agreement allows the Seller to terminate the agreement early or sell "Shortfall Sale Shares" to cover a "Prepayment Shortfall." If the shortfall is not covered, New Calidi may be required to pay cash or issue additional shares as liquidated damages.
Risks and Contingencies: The filing highlights risks regarding the ability to complete PIPE investments, regulatory approvals, and the potential disruption of Calidi's operations. Forward-looking statements are subject to uncertainties including global conflicts, the impact of the COVID-19 pandemic, and changes in the pharmaceutical regulatory landscape.
Investor Verification Checklist
- Verify the final closing date of the Business Combination and the exact number of shares redeemed versus non-redeemed.
- Confirm the total cash proceeds available to New Calidi post-closing, accounting for the $680,000 payment to the Seller and the $25.0 million Series B commitment.
- Monitor the "Reset Price" of the Forward Purchase Agreement for any downward adjustments due to dilutive offerings.
- Review the final composition of the New Calidi board of directors and the terms of the 2023 Stock Incentive Plan.
- Assess the impact of the Seller's waiver of redemption rights on the overall capital structure and perceived strength of the combination.